KBC Group NV Trims Holdings in DexCom, Inc. (NASDAQ:DXCM)

KBC Group NV trimmed its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 58.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 417,688 shares of the medical device company's stock after selling 579,068 shares during the period. KBC Group NV owned approximately 0.11% of DexCom worth $32,483,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of DXCM. Versant Capital Management Inc acquired a new stake in DexCom in the fourth quarter valued at approximately $25,000. Riverview Trust Co lifted its stake in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after buying an additional 232 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in shares of DexCom during the third quarter worth $57,000. Covestor Ltd lifted its stake in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company's stock worth $64,000 after buying an additional 335 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in shares of DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock worth $65,000 after buying an additional 265 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

DXCM traded up $0.77 on Tuesday, reaching $88.30. 3,408,033 shares of the company's stock were exchanged, compared to its average volume of 3,798,543. The stock has a market cap of $34.49 billion, a PE ratio of 52.87, a P/E/G ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock's fifty day moving average price is $79.73 and its 200-day moving average price is $76.70. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Raymond James lowered their price objective on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a research note on Friday, October 25th. Leerink Partners lowered their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Wells Fargo & Company lifted their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. Royal Bank of Canada lowered their price objective on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Finally, Sanford C. Bernstein raised their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $99.29.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the business's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.30% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.